Skip to main content (Press Enter).
Member Login
Skip auxiliary navigation (Press Enter).
CONTACT US
RHA
Voices
RSE
Education Station
Skip main navigation (Press Enter).
Toggle navigation
Search Options
Communities
All Discussions
All Communities
My Communities
Open Member Community
AKI, Billing & Reimbursement
Regional Communities
Staffing
Quality
Survey Preparedness
Directory
Member Directory
Participate
Join a Community
Resources
Community FAQs
Renal Services Exchange
Renew Your Membership
Education Station
Events
Event Description
Spotlight: Korsuva ™ - The 1st and only FDA-Approved Treatment for CKD-Associated Pruritus
When:
Feb 3, 2022 from 01:00 PM to 02:00 PM (ET)
Associated with
Open Member Community
share:
Korsuva ™ (Difelikefalin):
The 1
st
and only FDA-approved treatment for moderate to severe CKD-associated pruritus in adult hemodialysis patients
February 3, 2022
1:00 PM ET
The webinar will provide education around CKD-associated pruritus and the impact on the lives of hemodialysis patients. Also, we will be sharing clinical information on recently approved Korsvuva, the first and only FDA-approved treatment for moderate to severe pruritus associated with chronic kidney disease (CKD-aP) in adults undergoing hemodialysis (HD).
Learning Objectives
What is chronic kidney disease-associated pruritus?
Clinical study results of Korsuva ™ (Difelikefalin)
Overview of Korsuva ™ (Difelikefalin) reimbursement
More information
Location
Online Instructions:
Url:
http://www.pathlms.com/renal-healthcare-association/courses/38744
Login:
Download to Your Calendar
Skip Navigation Links
Communities
Directory
Participate
Resources
Copyright 2023 Connect. All rights reserved.
Powered by Higher Logic